Serum amyloid A levels are associated with polymorphic variants in the serum amyloid A 1 and 2 genes.
Biomarker
Cardiovascular disease (CVD)
Genetic variants
Serum amyloid A (SAA)
Journal
Irish journal of medical science
ISSN: 1863-4362
Titre abrégé: Ir J Med Sci
Pays: Ireland
ID NLM: 7806864
Informations de publication
Date de publication:
Nov 2019
Nov 2019
Historique:
received:
05
12
2018
accepted:
22
02
2019
pubmed:
11
3
2019
medline:
14
1
2020
entrez:
11
3
2019
Statut:
ppublish
Résumé
Serum amyloid A (SAA) is secreted by liver hepatocytes in response to increased inflammation whereupon it associates with high-density lipoprotein (HDL) and alters the protein and lipid composition of HDL negating some of its anti-atherogenic properties. To identify variants within the SAA gene that may be associated with SAA levels and/or cardiovascular disease (CVD). We identified exonic variants within the SAA genes by deoxyribonucleic acid (DNA) Sanger sequencing. We tested the association between SAA variants and serum SAA levels in 246 individuals with and without CVD. Increased SAA was associated with rs2468844 (beta [β] = 1.73; confidence intervals [CI], 1.14-1.75; p = 0.01), rs1136747 (β = 1.53 (CI, 1.11-1.73); p = 0.01) and rs149926073 (β = 3.37 (CI, 1.70-4.00); p = 0.02), while rs1136745 was significantly associated with decreased SAA levels (β = 0.70 (CI, 0.53-0.94); p = 0.02). Homozygous individuals with the SAA1.3 haplotype had significantly lower levels of SAA compared with those with SAA1.1 or SAA1.5 (β = 0.43 (CI, 0.22-0.85); p = 0.02) while SAA1.3/1.5 heterozygotes had significantly higher SAA levels compared with those homozygous for SAA1.1 (β = 2.58 (CI, 1.19-5.57); p = 0.02). We have identified novel genetic variants in the SAA genes associated with SAA levels, a biomarker of inflammation and chronic disease. The utility of SAA as a biomarker for inflammation and chronic disease may be influenced by underlying genetic variation in baseline levels.
Sections du résumé
BACKGROUND
BACKGROUND
Serum amyloid A (SAA) is secreted by liver hepatocytes in response to increased inflammation whereupon it associates with high-density lipoprotein (HDL) and alters the protein and lipid composition of HDL negating some of its anti-atherogenic properties.
AIMS
OBJECTIVE
To identify variants within the SAA gene that may be associated with SAA levels and/or cardiovascular disease (CVD).
METHODS
METHODS
We identified exonic variants within the SAA genes by deoxyribonucleic acid (DNA) Sanger sequencing. We tested the association between SAA variants and serum SAA levels in 246 individuals with and without CVD.
RESULTS
RESULTS
Increased SAA was associated with rs2468844 (beta [β] = 1.73; confidence intervals [CI], 1.14-1.75; p = 0.01), rs1136747 (β = 1.53 (CI, 1.11-1.73); p = 0.01) and rs149926073 (β = 3.37 (CI, 1.70-4.00); p = 0.02), while rs1136745 was significantly associated with decreased SAA levels (β = 0.70 (CI, 0.53-0.94); p = 0.02). Homozygous individuals with the SAA1.3 haplotype had significantly lower levels of SAA compared with those with SAA1.1 or SAA1.5 (β = 0.43 (CI, 0.22-0.85); p = 0.02) while SAA1.3/1.5 heterozygotes had significantly higher SAA levels compared with those homozygous for SAA1.1 (β = 2.58 (CI, 1.19-5.57); p = 0.02).
CONCLUSIONS
CONCLUSIONS
We have identified novel genetic variants in the SAA genes associated with SAA levels, a biomarker of inflammation and chronic disease. The utility of SAA as a biomarker for inflammation and chronic disease may be influenced by underlying genetic variation in baseline levels.
Identifiants
pubmed: 30852808
doi: 10.1007/s11845-019-01996-8
pii: 10.1007/s11845-019-01996-8
doi:
Substances chimiques
Biomarkers
0
Lipids
0
Lipoproteins, HDL
0
Serum Amyloid A Protein
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1175-1183Subventions
Organisme : Medical Research Council
ID : MC_PC_15025
Pays : United Kingdom
Organisme : NI HSC
ID : STL/4936/14
Organisme : Royal Victoria Hospital Heart Trust Fund
ID : RG14-9
Références
Arthritis Rheum. 2001 Jun;44(6):1266-72
pubmed: 11407685
ISRN Inflamm. 2012 May 06;2012:953461
pubmed: 24049653
J Diabetes Res. 2017;2017:1314864
pubmed: 28596970
PLoS One. 2010 Nov 16;5(11):e13997
pubmed: 21103356
Amyloid. 1999 Sep;6(3):199-204
pubmed: 10524285
J Rheumatol. 2004 Jun;31(6):1139-42
pubmed: 15170927
Am J Hum Genet. 2000 Nov;67(5):1136-43
pubmed: 11017802
Circulation. 2005 Mar 22;111(11):1355-61
pubmed: 15753219
Proc Natl Acad Sci U S A. 1994 Apr 12;91(8):3186-90
pubmed: 8159722
Chin Med J (Engl). 2009 Nov 5;122(21):2560-6
pubmed: 19951570
Proteomics Clin Appl. 2016 Nov;10(11):1077-1092
pubmed: 27274000
PLoS One. 2008;3(12):e3867
pubmed: 19057652
Curr Opin Hematol. 2000 Jan;7(1):64-9
pubmed: 10608507
PLoS One. 2013;8(2):e55227
pubmed: 23437051
Atherosclerosis. 2016 Jan;244:172-8
pubmed: 26647373
Amyloid. 2007 Dec;14(4):271-5
pubmed: 17968686
Amyloid. 2009 Dec;16(4):196-200
pubmed: 19922330
Eur J Clin Invest. 2001 Dec;31(12):1070-7
pubmed: 11903494
PLoS One. 2013 Jun 04;8(6):e64974
pubmed: 23750222
Genet Mol Res. 2014 May 09;13(2):3693-6
pubmed: 24854450
Arterioscler Thromb Vasc Biol. 2000 Mar;20(3):763-72
pubmed: 10712402
Arterioscler Thromb Vasc Biol. 2012 Sep;32(9):2045-51
pubmed: 22895665
J Lipid Res. 2005 Mar;46(3):389-403
pubmed: 15722558
Genomics. 1993 May;16(2):447-54
pubmed: 7686132
Biochem Biophys Res Commun. 2014 Jan 31;444(1):92-7
pubmed: 24440699
Clin Rheumatol. 2007 Jun;26(6):927-9
pubmed: 17039260
J Biol Chem. 1992 Feb 25;267(6):3862-7
pubmed: 1740433
Tissue Antigens. 2015 Mar;85(3):168-76
pubmed: 25656165
J Lipid Res. 2007 Jan;48(1):86-95
pubmed: 17065664
J Lipid Res. 2015 Feb;56(2):286-93
pubmed: 25429103
J Lipid Res. 2004 Jul;45(7):1169-96
pubmed: 15102878
J Neurol Sci. 2017 Sep 15;380:101-105
pubmed: 28870546
Hum Mol Genet. 1995 Jun;4(6):1083-7
pubmed: 7655463
Curr Med Chem. 2016;23(17):1725-55
pubmed: 27087246
Electrophoresis. 1996 May;17(5):866-76
pubmed: 8783012
J Exp Med. 1976 Oct 1;144(4):1121-7
pubmed: 978136